ALKERMES | ALKS - Interest Income


ALKERMES reported $8.54M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
AbbVie USD 59M 13M Dec/2025
Acadia Pharmaceuticals USD 8.33M 86K Dec/2025
ALKERMES USD 8.54M 3.59M Mar/2026
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Eli Lilly USD 65M 25M Sep/2025
Gilead Sciences USD 95M 7M Dec/2025
Heron Therapeutics USD 433K 277K Dec/2021
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
J&J USD 2.14 237M Mar/2026
Merck USD 69M 27M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Otsuka Holdings JPY 10.49B 396M Jun/2024
Pfizer USD 115M 51M Mar/2026
Regeneron Pharmaceuticals USD 193.3M 18.2M Dec/2025
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026